25 Oct 2017

Nextremity Solutions, Inc. Announces Full U.S. Commercial Launch of the Arcus™ Staple System

Warsaw, Indiana, October 25, 2017 — Nextremity

25 Oct 2017

Warsaw, Indiana, October 25, 2017 — Nextremity Solutions, Inc., a strategic commercialization organization with a focus on the musculoskeletal space, located in “The Orthopedic Capital of the World,” Warsaw, Ind., today announced the full release of the Arcus™ Staple System through its strategic alliance with Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare.

In October 2016, Zimmer Biomet announced an exclusive agreement with Nextremity Solutions to globally distribute the company’s foot and ankle deformity correction products. The initial three products to be distributed through this alliance included the Nextra® Hammertoe Correction System, Re+Line® Bunion Correction System, and the MSP™ Metatarsal Shortening System. Nextremity Solutions’ Arcus Staple System is the latest product to be added to Zimmer Biomet’s foot and ankle portfolio as part of this agreement.

During clinical trials, more than 200 Arcus staples were implanted during surgeries performed in facilities around the U.S.  During this micro-commercialization phase, Nextremity Solutions’ i3TM Strategic Solutions process was used to assess valuable surgeon feedback that led to improvements of the implant and instrumentation design.  The Arcus staple’s innovative arc design has been shown to provide greater and more sustained compression compared to competitive staples.1

  1. A Mechanical Evaluation of the Interfragmentary Compressive Forces of the Arcus Staple System, Lisa A. Ferra, Ph.D., Orthokinetic Technologies and Orthokinetic Testing Technologies, Southport, NC

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held strategic commercialization organization with a focus on the musculoskeletal space, offering innovative solutions and Revenue Ready™ products for various musculoskeletal applications and for the benefit of our industry partners. The Company’s procedure-ready, sterile implant systems include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.

Leave a comment
More Posts
Comments
Comment